Suppr超能文献

胰腺癌的R2切除——有意义吗?

R2 resection in pancreatic cancer--does it make sense?

作者信息

Köninger Jörg, Wente Moritz N, Müller-Stich Beat P, di Mola Francesco F, Gutt Carsten N, Hinz Ulf, Müller Michael W, Friess Helmut, Büchler Markus W

机构信息

Department of Surgery, University of Heidelberg, Heidelberg, Germany.

出版信息

Langenbecks Arch Surg. 2008 Nov;393(6):929-34. doi: 10.1007/s00423-008-0308-4. Epub 2008 Feb 29.

Abstract

BACKGROUND

The goal of surgical treatment in patients with pancreatic cancer is the complete resection of tumor tissue; however, the intraoperative appraisal of resectability can be difficult. Extensive surgical exploration for definitive clear resectability may lead to R2 resections in single cases.

PATIENTS

We analyzed 38 patients with pancreatic cancer with remaining macroscopic tumor tissue after pancreatic resection, as R0 resection was not possible. Patients were compared to 46 patients with unresectable cancer without distant metastases or peritoneal carcinomatosis, in which a bypass procedure was performed.

RESULTS

Operating time and hospital stay were significantly longer after R2 resection. Intraoperative blood loss was significantly higher; and severe surgical complications and the need for relaparotomy were significantly more frequent after R2 resection. The 30-day mortality rate was higher after R2 resection; this difference was not statistically significant. Median survival was comparable in both groups. Two years after surgery, 22.6% of the patients after R2 resection were still alive compared to 10.9% after bypass surgery.

CONCLUSION

Tumor debulking is not a treatment option in patients with advanced pancreatic cancer, but the patient is not at a disadvantage compared to bypass procedures if tumor tissue remains and R0 resection cannot be achieved after surgical exploration.

摘要

背景

胰腺癌患者手术治疗的目标是完整切除肿瘤组织;然而,术中评估肿瘤的可切除性可能存在困难。为明确可切除性而进行广泛的手术探查可能导致个别病例出现R2切除。

患者

我们分析了38例胰腺癌患者,这些患者在胰腺切除术后仍有肉眼可见的肿瘤组织,因为无法实现R0切除。将这些患者与46例不可切除的癌症患者进行比较,后者无远处转移或腹膜种植转移,进行了旁路手术。

结果

R2切除术后手术时间和住院时间显著延长。术中失血量显著增加;R2切除术后严重手术并发症和再次剖腹手术的需求显著更频繁。R2切除术后30天死亡率较高;但这一差异无统计学意义。两组患者的中位生存期相当。术后两年,R2切除术后患者的生存率为22.6%,而旁路手术后为10.9%。

结论

对于晚期胰腺癌患者,肿瘤减瘤术并非一种治疗选择,但如果手术探查后仍有肿瘤组织残留且无法实现R0切除,与旁路手术相比,患者并无劣势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验